drugset / Trial / NCT00028652

Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases

NCT00028652

Treatment

Summary

RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 gene therapy in treating patients who have skin metastases.

Timeline

Start
2002-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject interleukin-12 Protein / enzyme biologic Other